Icaritin‐induced immunomodulatory efficacy in advanced hepatitis B virus‐related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Icaritin‐induced immunomodulatory efficacy in advanced hepatitis B virus‐related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-09-05
DOI
10.1111/cas.14641
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
- (2019) Michael Teufel et al. GASTROENTEROLOGY
- First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers
- (2019) Ying Fan et al. BMC CANCER
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Icaritin promotes tumor T‐cell infiltration and induces antitumor immunity in mice
- (2019) Haibang Hao et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Therapeutic strategies for hepatitis B virus infection: towards a cure
- (2019) Gregory C. Fanning et al. NATURE REVIEWS DRUG DISCOVERY
- A global view of hepatocellular carcinoma: trends, risk, prevention and management
- (2019) Ju Dong Yang et al. Nature Reviews Gastroenterology & Hepatology
- HBV-Induced Immune Imbalance in the Development of HCC
- (2019) Yongyan Chen et al. Frontiers in Immunology
- STAT3, a Master Regulator of Anti-Tumor Immune Response
- (2019) Rébé et al. Cancers
- Joining the dots for better liver cancer treatment
- (2019) Lo-Kong Chan et al. Nature Reviews Gastroenterology & Hepatology
- Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma
- (2019) Stephen Lam Chan et al. Liver Cancer
- Jak-Stat Signaling Induced by Interleukin-6 Family Cytokines in Hepatocellular Carcinoma
- (2019) Lokau et al. Cancers
- Activation of PPARγ mediates icaritin-induced cell cycle arrest and apoptosis in glioblastoma multiforme
- (2018) Yongji Liu et al. BIOMEDICINE & PHARMACOTHERAPY
- Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
- (2018) Brandon W. Higgs et al. CLINICAL CANCER RESEARCH
- Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma
- (2018) Chun Jye Lim et al. GUT
- Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis
- (2018) Chong Wu et al. JOURNAL OF CLINICAL INVESTIGATION
- Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
- (2018) Eleonora De Martin et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Flavonoids as Th1/Th2 cytokines immunomodulators: A systematic review of studies on animal models
- (2018) Gopalsamy Rajiv Gandhi et al. PHYTOMEDICINE
- Icaritin Provokes Serum Thrombopoietin and Downregulates Thrombopoietin/MPL of the Bone Marrow in a Mouse Model of Immune Thrombocytopenia
- (2018) Ke Zhang et al. MEDIATORS OF INFLAMMATION
- Molecular therapies and precision medicine for hepatocellular carcinoma
- (2018) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions
- (2017) Rohit Loomba et al. GASTROENTEROLOGY
- High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B
- (2017) Gi-Ae Kim et al. GUT
- Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials
- (2017) Richard Jackson et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks
- (2017) Patrick Kennedy et al. Viruses-Basel
- Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma
- (2016) Martin H Voss et al. BRITISH JOURNAL OF CANCER
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Dynamic change of the systemic immune inflammation index predicts the prognosis of patients with hepatocellular carcinoma after curative resection
- (2016) Bei-li Wang et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review
- (2016) Soheil Tavakolpour et al. Hepatitis Monthly
- The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013
- (2016) Jeffrey D Stanaway et al. LANCET
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Screening and diagnosis of HBV in low-income and middle-income countries
- (2016) Jean-Pierre Allain et al. Nature Reviews Gastroenterology & Hepatology
- Icaritin inhibits the expression of alpha-fetoprotein in hepatitis B virus-infected hepatoma cell lines through post-transcriptional regulation
- (2016) Chao Zhang et al. Oncotarget
- Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C
- (2016) Ming-Ying Lu et al. Scientific Reports
- Polarization of Monocytic Myeloid-Derived Suppressor Cells by Hepatitis B Surface Antigen Is Mediated via ERK/IL-6/STAT3 Signaling Feedback and Restrains the Activation of T Cells in Chronic Hepatitis B Virus Infection
- (2015) Zhong Fang et al. JOURNAL OF IMMUNOLOGY
- Erratum: Advances in targeted therapies for hepatocellular carcinoma in the genomic era
- (2015) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- Big opportunities for small molecules in immuno-oncology
- (2015) Jerry L. Adams et al. NATURE REVIEWS DRUG DISCOVERY
- A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway
- (2015) Hong Zhao et al. Oncotarget
- Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials
- (2015) Ibrahim Jantan et al. Frontiers in Plant Science
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
- (2014) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Duration of Stable Disease Is Associated with Overall Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib
- (2014) Tadaaki Arizumi et al. DIGESTIVE DISEASES
- Tumor Necrosis Factor-Alpha Induced by Hepatitis B Virus Core Mediating the Immune Response for Hepatitis B Viral Clearance in Mice Model
- (2014) Horng-Tay Tzeng et al. PLoS One
- Cytokine patterns in patients with cancer: a systematic review
- (2013) Bodo E Lippitz LANCET ONCOLOGY
- JAKs and STATs in Immunity, Immunodeficiency, and Cancer
- (2013) John J. O'Shea et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
- (2012) J. S. Brooke CLINICAL MICROBIOLOGY REVIEWS
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial
- (2012) Ann-Lii Cheng et al. EUROPEAN JOURNAL OF CANCER
- Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions
- (2011) Junmin Zhou et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma
- (2011) Fang-Ming Gu et al. Molecular Cancer
- Icaritin Shows Potent Anti-Leukemia Activity on Chronic Myeloid Leukemia In Vitro and In Vivo by Regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT Signalings
- (2011) Jian feng Zhu et al. PLoS One
- Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression
- (2010) Eek Joong Park et al. CELL
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started